KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Finished Goods (2016)

AbbVie (ABBV) has disclosed Finished Goods for 5 consecutive years, with $556.0 million as the latest value for Q2 2016.

  • On a quarterly basis, Finished Goods rose 16.32% to $556.0 million in Q2 2016 year-over-year; TTM through Jun 2016 was $556.0 million, a 16.32% increase, with the full-year FY2015 number at $469.0 million, up 37.54% from a year prior.
  • Finished Goods was $556.0 million for Q2 2016 at AbbVie, up from $552.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $640.0 million in Q3 2015 to a low of $280.0 million in Q3 2014.
  • A 5-year average of $479.5 million and a median of $485.0 million in 2013 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: plummeted 41.42% in 2014, then skyrocketed 128.57% in 2015.
  • AbbVie's Finished Goods stood at $547.0 million in 2012, then decreased by 11.33% to $485.0 million in 2013, then fell by 29.69% to $341.0 million in 2014, then skyrocketed by 37.54% to $469.0 million in 2015, then grew by 18.55% to $556.0 million in 2016.
  • Per Business Quant, the three most recent readings for ABBV's Finished Goods are $556.0 million (Q2 2016), $552.0 million (Q1 2016), and $469.0 million (Q4 2015).